###begin article-title 0
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 69 93 69 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cysteine/tyrosine-rich 1</italic>
###xml 103 108 <span type="species:ncbi:9606">human</span>
Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 459 465 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 210 215 <span type="species:ncbi:9606">human</span>
###xml 473 478 <span type="species:ncbi:9606">human</span>
CYYR1 is a recently identified gene located on human chromosome 21 whose product has no similarity to any known protein and is of unknown function. Analysis of expressed sequence tags (ESTs) have revealed high human CYYR1 expression in cells belonging to the diffuse neuroendocrine system (DNES). These cells may be the origin of neuroendocrine (NE) tumors. The aim of this study was to conduct an initial analysis of sequence, splicing and expression of the CYYR1 mRNA in human NE tumors.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 219 221 219 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 292 294 292 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 437 443 437 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 672 678 672 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
The CYYR1 mRNA coding sequence (CDS) was studied in 32 NE tumors by RT-PCR and sequence analysis. A subtle alternative splicing was identified generating two isoforms of CYYR1 mRNA differing in terms of the absence (CAG- isoform, the first described mRNA for CYYR1 locus) or the presence (CAG+ isoform) of a CAG codon. When present, this specific codon determines the presence of an alanine residue, at the exon 3/exon 4 junction of the CYYR1 mRNA. The two mRNA isoform amounts were determined by quantitative relative RT-PCR in 29 NE tumors, 2 non-neuroendocrine tumors and 10 normal tissues. A bioinformatic analysis was performed to search for the existence of the two CYYR1 isoforms in other species.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 355 361 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 364 366 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 372 374 372 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 422 428 422 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 431 433 431 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 482 484 482 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 615 637 615 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pan troglodytes CYYR1 </italic>
###xml 615 630 <span type="species:ncbi:9598">Pan troglodytes</span>
The CYYR1 CDS did not show differences compared to the reference sequence in any of the samples, with the exception of an NE tumor arising in the neck region. Sequence analysis of this tumor identified a change in the CDS 333 position (T instead of C), leading to the amino acid mutation P111S. NE tumor samples showed no significant difference in either CYYR1 CAG- or CAG+ isoform expression compared to control tissues. CYYR1 CAG- isoform was significantly more expressed than CAG+ isoform in NE tumors as well as in control samples investigated. Bioinformatic analysis revealed that only the genomic sequence of Pan troglodytes CYYR1 is consistent with the possible existence of the two described mRNA isoforms.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
A new "subtle" splicing isoform (CAG+) of CYYR1 mRNA, the sequence and the expression of this gene were defined in a large series of NE tumors.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1</italic>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 809 815 809 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 429 435 <span type="species:ncbi:9606">humans</span>
The cysteine/tyrosine-rich 1 gene (CYYR1) is a large gene of 107 kb that we have previously identified [1] on human chromosome 21 (21q21.2). CYYR1 is composed of 4 small exons separated by three large introns and it encodes a small 154-amino acid polypeptide conserved in vertebrates. The most prominent feature of the protein family is the presence of a central cysteine- and tyrosine-rich domain, highly conserved from fish to humans and including a CCSYYAY box. There is also a proline-rich region, localized at carboxy-terminus, consisting of three repeated PPPY motifs. A putative transmembrane domain was identified in all proteins of the family by different prediction methods, along with a signal peptide suggesting the possible location of the CYYR1 protein in the cell or cell compartment membrane. CYYR1 product has no similarity to any known protein and its function is unknown.
###end p 11
###begin p 12
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 231 237 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 196 201 <span type="species:ncbi:9606">human</span>
###xml 265 270 <span type="species:ncbi:9606">human</span>
Two different CYYR1 mRNA species were identified using Northern blot analysis: they were consistent with two isoforms arising from alternative polyadenylation. The expression pattern of the CYYR1 human gene appears to be broad, as CYYR1 mRNA was detected in all 12 human tissues tested, except peripheral blood leukocytes [1].
###end p 12
###begin p 13
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1</italic>
###xml 912 913 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1012 1018 1012 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 65 70 <span type="species:ncbi:9606">human</span>
Valuable data about the function of the CYYR1 gene were added by human expressed sequence tag (EST) database analysis. This was possible because the main source of tissues and cells used in the construction of libraries, from which most of the CYYR1-related ESTs were retrieved, included carcinoid tumor of the lung, melanocytes, parathyroid tumor cells, fetal adrenal tissue, follicular carcinoma of the thyroid, pineal gland and gastrointestinal tissue. A common feature of all these tissues is that they are composed of or include cell types belonging to the dispersed neuroendocrine system (DNES). The term "neuroendocrine" has been used to define cells such as neurons and endocrine cells that secrete their products in a regulated manner in response to a specific stimulus, and share a common phenotypic program, characterized by the expression of specific markers such as neuropeptides and chromogranins [2]. These cell types are typical of vertebrates and the EST expression data are consistent with the CYYR1 phylogenetic analysis.
###end p 13
###begin p 14
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
It is assumed that NE tumors can originate from normal NE cells. NE tumors are divided, according to the WHO (World Health Organization) classification, into well-differentiated tumors or carcinomas, poorly differentiated carcinomas and mixed endocrine-exocrine carcinomas [3], according to their histological and cytological features.
###end p 14
###begin p 15
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 96 101 <span type="species:ncbi:9606">human</span>
The aim of this study was to analyze the sequence, splicing and expression of the CYYR1 gene in human neuroendocrine tumors. First, the CYYR1 mRNA coding sequence (CDS) was studied in a large series of NE tumors and a P111S mutation in the only neck-derived tumor was identified. Sequence analysis also allowed us to identify a "subtle" splicing isoform due to the existence of two functional acceptor splicing sites in the sequence CAGCAG at the 3' end of intron 3. Both isoforms, which encode two polypeptides - differing in terms of the absence or presence of one amino acid - were found in normal and neoplastic tissues. Their relative expression was investigated by a quantitative relative RT-PCR (reverse transcription - polymerase chain reaction) method.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Sample collection
###end title 17
###begin p 18
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Sample selection was focused on neuroendocrine tumors from multiple anatomic sites (mostly from the digestive system) with varying differentiation grades (see Additional file 1). Tumors were classified according to the WHO classification of endocrine tumors [3]. The specimens were obtained from 16 males and 11 females ranging between 43 and 79 years of age (mean age of 63.6 years). We used representative portions of 32 tumor specimens (see Additional file 1) labelled NE 1 to NE 32 (15 samples: well differentiated endocrine carcinomas, WDEC; 13 samples: poorly differentiated endocrine carcinomas, PDEC; 4 samples: mixed exocrine-endocrine tumors, MEET). Samples were collected for the H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL) Tissue Procurement Facility, under institutional review board protocols. The resection-to-preservation (freezing) time was kept to less than twenty minutes. Sample storage consisted of liquid nitrogen (n = 30) and -80degreesC (n = 2) for a mean storage period of 41.65 months. Prior to RNA isolation, twelve of these tumor samples underwent independent pathological review by a single pathologist (DC) and were macrodissected while frozen to select tumor-rich areas and decrease the amount of stroma and non-neoplastic elements surrounding the target tumor tissue.
###end p 18
###begin title 19
RNA sources
###end title 19
###begin p 20
###xml 324 329 <span type="species:ncbi:9606">human</span>
Total RNA from the NE samples was extracted using the TRIzol (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's protocol. Due to the absence of tissues entirely composed of DNES cells, which are by definition part of a diffuse system of cells, a set of 8 commercial total RNA samples from several whole normal human organs was used as control: prostate (pool of 16 normal adult whole prostates), brain (one normal adult whole brain), heart (one normal adult whole heart), colon (pool of 2 normal adult colons), small intestine (pool of 2 normal adult small intestines), stomach (pool of 15 normal adult stomachs), thymus (pool of 13 normal adult thymuses) and skeletal muscle (pool of 2 normal adult skeletal muscles). All RNA samples were purchased from BD Biosciences Clontech (Palo Alto, CA, USA).
###end p 20
###begin p 21
###xml 617 622 <span type="species:ncbi:9606">human</span>
In order to compare the RNA expression of some NE tumor samples (metastatic liver, pancreas and breast tumors) with non-neuroendocrine tumors and corresponding normal tissues, commercial total RNAs from 2 non-neuroendocrine tumors (pancreas and breast tumors) and from the 2 corresponding normal tissues were used in a second experiment. The non- neuroendocrine tumor total RNAs were obtained from a pancreas acinar cell carcinoma (T2N0M0, stage 1B) and from a breast invasive ductal carcinoma (T4N1M0, stage 3B), and were purchased from Ambion (Austin, TX, USA). The 2 normal total RNAs were from a pancreas (normal human pancreas pooled from a 35-year-old Caucasian male) and a breast (normal adult mammary gland pooled from a 27-year-old Caucasian female), and were purchased from BD Biosciences Clontech.
###end p 21
###begin p 22
RNA was quantified using both UV spectrophotometry and standard agarose gel. Quantification of electrophoresed RNA was obtained by comparison with standard markers using the gel imaging system Gel Doc 2000 (Bio-Rad, Hercules, CA, USA).
###end p 22
###begin title 23
Primer design
###end title 23
###begin p 24
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 179 192 179 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens </italic>
###xml 254 267 254 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens </italic>
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1</italic>
###xml 179 191 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 254 266 <span type="species:ncbi:9606">Homo sapiens</span>
The primers for amplifications were designed using the Amplify software [4], following standard criteria [5]. The data source for primer design was the GenBank sequence AP001696, Homo sapiens genomic DNA, chromosome 21 q, section 40/105 [GenBank:] and , Homo sapiens cysteine/tyrosine-rich 1 (CYYR1) mRNA [GenBank:].
###end p 24
###begin p 25
For the CDS sequence analysis, we designed the forward primer #1 5'-GCTGCTCTCTCCATCTGATCGC-3' (based on exon 1) and the reverse primer #2 5'-ATTCCAGGCAAGATCGCCCATTG-3' (based on exon 4). The size of the expected PCR product was 605 bp.
###end p 25
###begin p 26
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 230 232 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 549 555 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 558 560 558 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 611 617 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 620 622 620 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
For the quantitative relative CYYR1 CAG-/CAG+ analysis, we designed three primers: a forward primer common to both mRNA forms (#3 5'-GTCTTGCTTCCGAAGTTGGTCCTGC-3'), based on exon 1, and two specific reverse primers for CAG- and CAG+ forms, respectively. Each reverse oligonucleotide was based on the exon 3/exon 4 boundary, and was specific for only one of the two isoforms, containing two mismatches at the last three bases of the 3' end, one being the 3'-residue compared to the sequence of the other isoform (#4 5'-GTGACCGTAGGGTGGTGGTCCAGG-3' for CYYR1 CAG- form, primer #5 5'-GTGACCGTAGGGTGGTGGTCCTGC-3' for CYYR1 CAG+ form). The expected size of PCR product was 321 bp with primers #3 and #4, and 324 bp with primers #3 and #5.
###end p 26
###begin p 27
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
To amplify the beta-2 microglobulin (B2M) housekeeping gene for RNA quantity normalization in quantitative relative RT-PCR analysis [6], we used forward primer #6 5'-GCGGGCATTCCTGAAGCTGACAGCA-3' and reverse primer #7 5'-TACATCAAACATGGAGACAGCACTC-3', with an expected PCR product size of 586 bp.
###end p 27
###begin title 28
RT-PCR
###end title 28
###begin p 29
###xml 123 152 <span type="species:ncbi:11801">Moloney murine leukemia virus</span>
For all samples, total RNA (2 mug) was reverse transcribed at 37degreesC for 60 min in 50 muL of final volume using cloned Moloney murine leukemia virus reverse-transcriptase 400 U (Promega, Madison, WI; used with companion buffer), 2.5 muM oligo dT-15, 2 muM random hexamers and 500 muM of each dNTP (deoxyribonucleotide triphosphate).
###end p 29
###begin p 30
###xml 238 239 236 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
PCR experiments to obtain amplicons for sequence analysis were performed in 50 muL final volume, containing 5 muL reverse transcription mix, 1 U Taq Polymerase (TaKaRa, Shiga, Japan) with companion reagents (0.2 mM of each dNTP, 2 mM MgCl2, 1x PCR buffer), and 0.3 muM of each primer. An initial denaturation step of 2 min at 94degreesC was followed by amplification for 40 cycles, (30 sec at 94degreesC, 30 sec at 63degreesC, 45 sec at 72degreesC) and final extension for 7 min at 72degreesC.
###end p 30
###begin p 31
###xml 242 243 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
PCR experiments for quantitative relative analysis were performed in 30 muL of final volume, containing 3 muL of reverse transcription mix, 0.6 U of Taq Polymerase (TaKaRa, Shiga, Japan) with companion reagents (0.2 mM of each dNTP, 2 mM MgCl2, 1x PCR buffer), and 0.2 muM of each primer.
###end p 31
###begin p 32
###xml 125 127 125 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 562 565 562 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 567 573 567 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 576 578 576 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 582 588 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 591 593 591 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 843 846 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 855 861 849 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 864 866 858 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 872 873 866 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
To standardize all PCR reactions for quantitative relative analysis, we prepared a single mix with PCR buffer 1x, dNTPs, MgCl2 and Taq Polymerase. Subsequently, this mix was dispensed into three aliquots and a different primer pair was added to each one. The cDNA samples were added after each mix has been divided into individual tubes. Each PCR reaction was performed in duplicate. In preliminary PCR experiments, we evaluated PCR products after 20, 25, 30, 35, 40 and 45 cycles (data not shown), in order to find the conditions allowing the quantification of B2M, CYYR1 CAG- and CYYR1 CAG+ RT-PCR products, respectively, at the maximum distance from the cycle corresponding to the reaction plateau. PCR reactions were performed with high stringency: an initial denaturation step of 2 min at 94degreesC was followed by amplification for 25 (B2M) or 35 (CYYR1 CAG- or CAG+) cycles (30 sec at 94degreesC, 30 sec at 63degreesC, 45 sec at 72degreesC), and a final extension for 7 min at 72degreesC.
###end p 32
###begin p 33
###xml 123 135 123 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RNA sources </italic>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 479 485 479 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
In a first experiment, 32 NE tumor samples were studied along with the standard set of 8 normal tissues (see the paragraph RNA sources above). In a second experiment, 17 NE tumor samples (nn. NE 1, NE 2, NE 4-8, NE 10-12, NE 14, NE 18, NE 20, NE 25, NE 27, NE 29-30 in the Additional file 1) from the liver, pancreas and breast were compared with the above described second control set of 2 normal tissues and 2 non-neuroendocrine tumor samples. In this case, the PCR cycles for CYYR1 isoforms were 40.
###end p 33
###begin title 34
Sequence analysis
###end title 34
###begin p 35
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
The CYYR1 CDS RT-PCR products obtained as described above were gel analyzed following standard methods [7], purified using GenElute PCR Clean-up kit (SIGMA, St. Louis, MO), and then subjected to automated sequence analysis of both DNA strands for each fragment, with the same primers used in the PCR reactions. The BigDye chain-terminator method was used with an automated ABI 310 DNA sequencer (Perkin-Elmer, Foster City, CA).
###end p 35
###begin p 36
Point mutation in sample NE 16 was confirmed by four independent RT-PCR reactions.
###end p 36
###begin title 37
Enzymatic digestion
###end title 37
###begin p 38
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 9 11 9 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 64 68 64 68 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CA|G</underline>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 173 175 173 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 222 228 222 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
CYYR1 CAG+ isoform sequence presents a PstI restriction site CTGCA|G, where the vertical bar indicates the cut position, so PstI was used to selectively digest the CYYR1 CAG+ amplification product. Enzymatic digestions of CYYR1 CDS RT-PCR products from normal brain and one NE tumor (sample NE 16) obtained with primers #1 and #2 were performed in 20 muL final volume, containing 200-300 ng amplicon and 13 U PstI enzyme (SIGMA, St. Louis, MO) with 1x buffer H. An overnight incubation at 37degreesC was performed. The digested products (10 muL) were separated into 1.5% agarose TBE (Tris-Borate-EDTA) gel stained with ethidium bromide and detected under ultraviolet light.
###end p 38
###begin title 39
Gel imaging and quantitative relative analysis
###end title 39
###begin p 40
###xml 135 138 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 140 146 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 149 151 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 155 161 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 164 166 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
For quantitative relative analysis, 10 muL aliquots of each PCR product were separated into 1.5% agarose TAE (Tris-Acetate-EDTA) gels. B2M, CYYR1 CAG- and CYYR1 CAG+ RT-PCR products from the same RNA samples were separated into the same gel. Marker M5 (Fermentas, Hanover, Maryland, MD) at two different dilutions was used as a quantitative reference. After separation, the gels were stained in TAE buffer containing ethidium bromide (0.5 mug/mL) and detected under ultraviolet light in "unsaturated" pixel modality with the Gel Doc 2000 Imaging System. Digital images were quantified and analyzed using Quantity One software (Bio-Rad, Hercules, CA, USA).
###end p 40
###begin p 41
Intensity values of the PCR product bands were calculated in comparison with a regression line, with the correlation coefficient >/= 0.99, generated from measurements of at least four Marker M5 bands of different concentration values. In particular, we used the "Volume Rect Tool" function to acquire pixel intensity data for each band. The gel image background was always subtracted.
###end p 41
###begin title 42
Statistical analysis
###end title 42
###begin p 43
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1</italic>
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 293 299 293 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 417 419 417 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The mean for each replicate data point and, in order to normalize the CYYR1 expression level, the CYYR1/B2M product mass ratio were determined. The statistical analysis was performed using JMP software, ver. 5 (SAS Institute, Cary, NC, USA). The unpaired t-test was used to compare normalized CYYR1 expression levels between normal and tumoral tissues, as well as to compare relative expression of CYYR1 CAG- with CAG+ isoforms.
###end p 43
###begin p 44
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 72 74 72 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 86 88 86 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 108 110 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The ANOVA test was performed to compare CYYR1 expression levels (for CAG- isoform, CAG+ isoform and CAG-/CAG+ ratio) among each different hystological subclass of the tumors studied in the first experiment.
###end p 44
###begin p 45
###xml 45 47 45 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Differences were considered significant with p < 0.05.
###end p 45
###begin title 46
Bioinformatic analysis
###end title 46
###begin p 47
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 79 81 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 418 423 <span type="species:ncbi:9606">human</span>
###xml 432 437 <span type="species:ncbi:10090">mouse</span>
In order to study the evolution of "subtle" splicing [8] of the CYYR1 mRNA (CAG- and CAG+ isoforms), CYYR1 mRNA encompassing the point alternatively spliced - [GenBank:] from base 556 to 757 - as well as the CYYR1 product amino acid sequence were analyzed by BLAST (Basic Local Alignment Search Tool) family programs with default parameters. This was done using the following GenBank divisions: "nr" (non redundant), "human ESTs", "mouse ESTs" and "other ESTs" database sequences. The same protocol was used to search for sequences harboring the new mutation described in one NE sample.
###end p 47
###begin title 48
Results
###end title 48
###begin title 49
RT-PCR - sequence analysis
###end title 49
###begin p 50
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
The RT-PCR amplification products for CYYR1 CDS mRNAs were successfully obtained from all the 32 NE RNA samples. In all cases, gel electrophoresis analysis revealed a single band of the expected size.
###end p 50
###begin p 51
Electrophoretograms showed a peak frameshift following the boundary between exon 3 and exon 4, consistently observed in both forward and reverse directions of the sequencing reaction. Visual analysis of the peaks suggested the simultaneous presence of two sequences differing by a three-base insertion in all of the samples analyzed (data not shown).
###end p 51
###begin p 52
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
In addition, the CYYR1 CDS sequence did not show differences from the GenBank reference in any of the analyzed samples except in sample NE 16, where a variation (apparently in heterozygotic form) in position 333 of CDS (T replaces C) led to a P111S amino acid change (Figure 1).
###end p 52
###begin p 53
###xml 566 567 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
A single nucleotide polymorphysm (SNP) at position 201 with respect to reference CDS (C replaces T at third position of codon 67, exon 3) was observed in heterozygosis (15 cases: NE 1, NE 4-9, NE 12, NE 15, NE 16, NE 18-20, NE 23, NE 31) or homozygosis (8 cases: NE 17, NE 24-27, NE 29, NE 30, NE 32). This base substitution transforms the codon 67 GTT into the codon GTC; in both cases, the coded amino acid is valine (V). This polymorphysm was present in the single nucleotide polymorphysm database (dbSNP) at NCBI (National Center for Biotechnology Information) [9] as cluster rs966410 (heterozygosity: 0.492).
###end p 53
###begin title 54
Enzymatic digestion
###end title 54
###begin p 55
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 197 203 197 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 206 208 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 251 253 251 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 270 272 270 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
In order to confirm the presence of two isoforms, an enzymatic digestion of CYYR1 CDS RT-PCR products from normal brain and one NE tumor (sample NE 16) was performed with PstI enzyme, specific for CYYR1 CAG+ isoform digestion. Expected size bands (CAG- form: 605 bp, CAG+ form: 427 bp and 181 bp) were obtained in both samples (Figure 2).
###end p 55
###begin title 56
Quantitative relative RT-PCR analysis
###end title 56
###begin p 57
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 52 54 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
The RT-PCR amplification products for B2M, CYYR1 CAG- and CYYR1 CAG+ mRNAs were successfully obtained in duplicate from 29 NE RNA samples and from 8 normal RNA controls. 3 out of 32 cases (NE 13, NE 24 and NE 28) were not considered in the analysis due to failure in obtaining data in duplicate. In all cases, gel electrophoresis analysis revealed single bands of the expected size (Figure 3).
###end p 57
###begin p 58
###xml 102 105 102 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 116 118 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
The gel images acquired in UV light and in "unsaturated pixel" mode were analyzed. RT-PCR products of B2M, CYYR1 CAG- and CYYR1 CAG+ mRNAs obtained from the same sample were electrophoresed in the same gel (Figure 3).
###end p 58
###begin p 59
This process generated two replicate data points, expressed as PCR product ng, which were used for subsequent elaborations.
###end p 59
###begin p 60
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 361 362 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 421 422 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 603 605 603 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Duplicate products for each gene were compared to evaluate the method reliability. In the first experiment, the mean percentage of difference between the two replicate measurements and the respective mean value for 29 NE tumor samples and 8 normal tissues was: 3.6% (tumors) or 2.5% (normal samples) for B2M, 3.8% (tumors) or 3.1% (normal samples) for CYYR1 CAG-, and 15.8% (tumors) or 8.9% (normal samples) for CYYR1 CAG+. The percentage of difference between the two replicate measurements and the respective mean value was lower than 13% for all the genes in all the samples, except for the CYYR1 CAG+ isoform values in 10 tumor samples and 1 normal sample, where the 16.3-61.2% range difference was due to the presence of values situated near to the lowest detectable level. The mean value of the two measurements was then routinely used in the statistical comparisons.
###end p 60
###begin p 61
###xml 278 281 278 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 339 340 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 407 408 407 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 450 456 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 459 461 459 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 809 813 809 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 844 850 844 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 853 855 853 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1184 1186 1184 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
In the second experiment, the mean percentage of difference between the two replicate measurements and the respective mean value for 17 NE tumor samples and 4 control samples (2 non-neuroendocrine tumors and 2 normal tissues) was: 4.0% (NE tumors) or 3.8% (control samples) for B2M, 4.8% (NE tumors) or 5.8% (control samples) for CYYR1 CAG-, and 16.2% (13 NE tumors) or 13.1% (control samples) for CYYR1 CAG+. Inconsistent duplicate measurements for CYYR1 CAG+ isoform were observed in 4 samples, due to values being in the lowest range of detection, so these samples (NE 10, NE 12, NE 25, and NE 30) were not considered for further analysis. The percentage of difference between the two replicate measurements and the respective mean value was lower than 15% for all the genes in all the samples, except for B2M in one NE tumor sample and the CYYR1 CAG+ isoform values in 5 tumor samples and 1 control sample, where the 17.4-54.8% range difference was due to the presence of values situated near to the lowest detectable level. The mean value of the two measurements was then routinely used in the statistical comparisons. In 7 cases (6 NE tumors and 1 normal tissue sample), the CAG+ isoform value was under the minimum detectable (0.25 ng) and it was considered 0.24 to allow calculations, with results analogous to those obtained when the corresponding samples were omitted from the statistical analysis.
###end p 61
###begin title 62
Statistical analysis
###end title 62
###begin p 63
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
All differences among CYYR1 mRNA isoform expression levels refer to RT-PCR product mass, normalized as described in the "Methods" section.
###end p 63
###begin p 64
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 76 78 76 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 85 87 85 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 250 256 250 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 259 260 259 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 264 266 264 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 458 464 452 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 467 469 461 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 593 595 587 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 716 722 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 725 727 713 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 935 937 917 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 943 945 925 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1073 1074 1055 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
In the first experiment, assessable replicate data points for B2M, CYYR1 CAG- and CAG+ mRNAs were successfully obtained for 29 out of 32 total samples tested; NE 13, NE 24 and NE 28 were not evaluated due to technical problems. The difference in the CYYR1 CAG-/CAG+ mRNA isoform ratio between tumors and normal tissues was not statistically significant (mean +/- standard deviation: tumors (n = 29), 19.3 +/- 32.6; normal tissues (n = 8), 10.9 +/- 6.3). The CYYR1 CAG- expression level was significantly lower in tumor samples in comparison with normal tissues at an approximate ratio of 2:3 (p = 0.022; mean +/- standard deviation: tumors, 0.92 +/- 0.25; normal tissues, 1.31 +/- 0.76), while the difference in the CYYR1 CAG+ expression level between tumors and normal tissues was not significant (mean +/- standard deviation: tumors, 0.15 +/- 0.13; normal tissues, 0.15 +/- 0.10). No statistical difference was observed in either CAG- or CAG+ isoform expression, or between macrodissected (n = 11) and non-macrodissected (n = 18) NE sample subgroups (see Additional file 1).
###end p 64
###begin p 65
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 360 366 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 369 371 363 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 526 532 514 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 535 537 523 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 772 774 754 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 780 782 762 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 832 833 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 845 846 827 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 882 883 864 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 895 896 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 946 947 928 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
In the second experiment, the difference in the CYYR1 CAG-/CAG+ mRNA isoform ratio between NE tumors (n = 13) and control tissues (2 non-neuroendocrine and 2 normal corresponding tissues; n = 4) was not statistically significant (mean +/- standard deviation: NE tumors (n = 13), 321.0 +/- 359.0; control tissues (n = 4), 80.8 +/- 138.7). The difference in the CYYR1 CAG- expression level (mean +/- standard deviation: NE tumors (n = 17), 0.43 +/- 0.17; control tissues (n = 4), 0.57 +/- 0.18) as well as the difference in the CYYR1 CAG+ expression level (mean +/- standard deviation: NE tumors (n = 13), 0.016 +/- 0.021; control tissues (n = 4), 0.05 +/- 0.06) between NE tumors and control tissues was not significant. No statistical difference was observed in either CAG- or CAG+ isoform expression, or between macrodissected (CAG-, n = 8; CAG+, n = 6) and non-macrodissected (CAG-, n = 9; CAG+, n = 7) NE sample subgroups (see Additional file 1).
###end p 65
###begin p 66
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 279 281 279 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 288 289 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 293 295 293 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
Differences among subclasses defined according to the WHO classification were investigated in the 29 samples for which data were obtained in the first experiment (15 WDEC, 11 PDEC and 3 MEET samples) using the ANOVA test, and they were not statistically significant for CAG-, CAG+ and CAG-/CAG+ CYYR1 isoform expression levels.
###end p 66
###begin p 67
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 37 39 37 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 88 90 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 262 264 262 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 290 292 290 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 358 360 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 387 389 387 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
In all samples studied, the CYYR1 CAG- isoform was expressed at an higher level than CAG+ isoform. The difference was highly statistically significant when comparing the respective expression levels for each isoform in the first experiment (29 NE tumor samples, p < 0.01; 8 normal tissues, p < 0.01) as well as in the second experiment (13 NE tumor samples, p < 0.01; 4 control tissues, p < 0.01).
###end p 67
###begin title 68
Bioinformatic analysis
###end title 68
###begin p 69
###xml 206 208 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1</italic>
###xml 370 372 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 403 405 403 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
Bioinformatic analysis was conducted using database versions available in April 2006. In "nr" database, 6 human mRNA sequences encompassing the variant splice point were found: 5 of which related to the CAG- first described isoform. In "human ESTs" database, 14 mRNA sequences relating to CYYR1, assignable to one of the two isoforms, were identified: 6 entries with CAG+ sequence and 8 entries with CAG- sequence (see Additional file 2).
###end p 69
###begin p 70
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 131 132 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 136 138 136 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 362 375 362 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus </italic>
###xml 390 408 390 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 419 425 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 514 516 514 516 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AG</underline>
###xml 552 558 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 561 563 561 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 362 374 <span type="species:ncbi:10090">Mus musculus</span>
###xml 390 407 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 546 551 <span type="species:ncbi:9606">human</span>
Figure 4 shows the alignment of the CYYR1 gene family nucleotide sequences present in the GenBank database and encompassing the CAG-/CAG+ exon junction. We considered only species for which at least one mRNA sequence or two EST sequences were available, and this homology was significant at least in allowing alignment at nucleotide level using BLAST. Exon 4 of Mus musculus [GenBank:] and Rattus norvegicus [GenBank:] CYYR1 begins with the TGG sequence, which does not offer a second splicing signal, unlike the CAG sequence at the beginning of human CYYR1 CAG+ exon 4 [GenBank:].
###end p 70
###begin p 71
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 185 196 185 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bos taurus </italic>
###xml 213 230 213 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Canis familiaris </italic>
###xml 242 255 242 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus </italic>
###xml 270 288 270 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 304 310 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 446 448 446 448 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AG</underline>
###xml 495 497 495 497 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AG</underline>
###xml 589 591 589 591 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AG</underline>
###xml 185 195 <span type="species:ncbi:9913">Bos taurus</span>
###xml 213 229 <span type="species:ncbi:9615">Canis familiaris</span>
###xml 242 254 <span type="species:ncbi:10090">Mus musculus</span>
###xml 270 287 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 420 426 <span type="species:ncbi:9606">humans</span>
The genomic sequences available for this junction all come from mammalian species, and we compared 57 bases at 3' of intron 3 and 25 bases at 5' of exon 4 (Figure 5A). The sequences of Bos taurus [GenBank htgs:], Canis familiaris [GenBank:], Mus musculus [GenBank:] and Rattus norvegicus [GenBank htgs:] CYYR1 at genomic level are clearly not consistent with the possibility of an alternative splicing as is possible in humans, because only one CAG sequence, therefore one acceptor splice site (AG), is present at the 3' intronic boundary, and the next exon begins with the TGG sequence (CAG//TGG, where//indicates intron/exon boundary).
###end p 71
###begin p 72
###xml 30 46 30 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pan troglodytes </italic>
###xml 84 97 84 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens </italic>
###xml 290 292 290 292 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AG</underline>
###xml 295 297 295 297 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AG</underline>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 30 45 <span type="species:ncbi:9598">Pan troglodytes</span>
###xml 47 57 <span type="species:ncbi:9598">Chimpanzee</span>
###xml 84 96 <span type="species:ncbi:9606">Homo sapiens</span>
In the anthropomorphic monkey Pan troglodytes (Chimpanzee) [GenBank:] as well as in Homo sapiens [GenBank:] the genomic sequence corresponding to intron 3/exon 4 boundary is CAGCAG. In this case, at the intron/exon junction, there are two successive splice sites separated by three bases (CAG//CAG) (Figure 5A).
###end p 72
###begin p 73
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
This genomic region is highly conserved, and it contains a similar putative branch site upstream of polypyrimidine tracts of various length and composition (Fig. 5B).
###end p 73
###begin p 74
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 268 269 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 273 275 273 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 556 557 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 621 623 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 345 352 <span type="species:ncbi:9913">bovines</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
Figure 6 shows the alignment of the vertebrate CYYR1 putative protein sequences available in GenBank (nr or EST divisions) or inferred by nucleotide sequences available (see Additional file 2). Alignment underlines that the encoded amino acids corresponding to the CAG-/CAG+ exon junction in the CYYR1 mRNA are well conserved from amphibians to bovines. Two amino acids conserved in all analyzed species (YP) are always followed by a couple of amino acids, one of which is always alanine (A): the same amino acid encoded by the rarer human mRNA isoform CAG+. In fish, a conserved block is found downstream of the CAG-/CAG+ exon junction.
###end p 74
###begin p 75
No sequence with NE 16 mutation was found in the analyzed databases.
###end p 75
###begin title 76
Discussion
###end title 76
###begin p 77
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 323 329 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 469 475 469 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 612 618 612 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 354 359 <span type="species:ncbi:9606">human</span>
###xml 663 668 <span type="species:ncbi:9606">human</span>
Neuroendocrine cells in the organism are part of a diffuse system of cells with neuroendocrine features characterized by ultrastructural features (presence of dense core granules of 100-400 nm diameter) and immunohistochemical phenotypes (pan-neuroendocrine markers and specific hormonal products) [10]. We first described CYYR1 gene as a novel locus on human chromosome 21, encoding a product with no similarity to any known protein. Based on the observation that the CYYR1 gene appears to be expressed, as evaluated by EST database analysis, in several types of neuroendocrine cells, we decided to investigate CYYR1 sequence and expression in a large series of human NE tumors. We also wanted to obtain new data about the CYYR1 gene, which has never been studied in-depth and whose product function is, at the moment, unknown.
###end p 77
###begin p 78
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 349 354 <span type="species:ncbi:9606">human</span>
Sequence analysis of the 32 NE samples tested showed a CDS sequence identical to that previously described in normal subjects, except for a case in which we identified a point mutation. The mutation is a C-T transition, apparently in heterozygotic state, leading to a P111S change predicted in the encoded product. This change is not present in any human sequence obtained from either finished sequence or EST databases. The replaced proline amino acid is situated one position before the first PPPY motif, which is present in three copies in the carboxy-terminus of the CYYR1 protein. This motif is known to be present in some viral proteins, where it is required for virus budding [11], and it is also described in proteins involved in interactions between cytoskeleton and extracellular matrix [12,13]. Due to the general relevance of proline for protein structure, and to its proximity to a functional motif, it may be speculated that this change could affect the CYYR1 function. Interestingly, the only NE mutated sample among those analyzed is a tumor arising in the neck region, a less common site of origin of neuroendocrine tumors.
###end p 78
###begin p 79
In addition, a known SNP has been found in some samples: a C-T change at the third position of codon 67.
###end p 79
###begin p 80
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 829 830 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Sequence analysis was also useful to show an unexpected "subtle" splicing isoform of CYYR1 mRNA, derived from the alternative use of an AG acceptor splice site located at the 3' end of CYYR1 intron 3, leading to the generation of mRNA isoforms which differentiate by only three bases. This new isoform encodes a predicted product with an adjunctive alanine (A) amino acid at position 112, located just before the glycine (G) preceding the first PPPY motif (Figure 6). Due to its position, it is likely that this adjunctive amino acid could affect CYYR1 function, allowing the presence of two protein products whose relative expression is regulated by alternative splicing. Alternative splicing leading to mRNA isoforms encoding slightly different polypeptides had been reported only anecdotally until a recent systematic survey [8]. This work has demonstrated the relative frequency of this phenomenon in several vertebrate genomes, underlining its biological relevance as a means to increase functional complexity generated by the same locus sequence.
###end p 80
###begin p 81
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 426 428 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 466 472 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 649 654 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF1R</italic>
###xml 682 688 682 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF1R </italic>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 972 978 972 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 981 982 981 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 986 988 986 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1027 1029 1027 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1035 1037 1035 1037 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1157 1163 1157 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 1220 1225 1220 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1</italic>
###xml 196 201 <span type="species:ncbi:9606">human</span>
Systematic analysis by RT-PCR proved that both isoforms are expressed in all 29 NE and 8 normal tissue samples investigated, with the constant prevalence of the CAG- isoform, as also confirmed by human EST database analysis. We also accurately quantify the relative expression of the two forms, using an approach whose reliability we have previously described [14]. We found that the most commonly expressed isoform is the CAG- isoform, the first described mRNA for CYYR1 locus [1]. The ratio between the expression of the two isoforms shows a greater variability with respect to a comparable gene such as the insulin-like growth factor 1 receptor (IGF1R). We previously found that IGF1R undergoes a "subtle" splicing with a tight regulation in both normal and neoplastic cells, leading to a constant 3:1 ratio [14]. However, when organs similar to those in which tumors arose were used as controls, statistical analysis failed to identify a significant difference in the CYYR1 CAG-/CAG+ ratio, as well as in the normalized CAG+ or CAG- mRNA level, between NE and normal samples. The EST database seems to support, for several tissues, a high expression of CYYR1 in some neuroendocrine tumors. For example, among the 19 CYYR1-related ESTs with "lung" origin, 12 are derived from lung carcinoid, and among the 12 ESTs with "pancreas" origin, 11 are derived from insulinoma. However, 10 of the lung carcinoid ESTs derive from the same library, as well as all the insulinoma ESTs. In general, EST database may provide indications about gene expression profile, but data are of limited statistical value.
###end p 81
###begin p 82
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 155 161 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 220 232 220 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Homo sapiens</italic>
###xml 243 259 243 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pan troglodytes </italic>
###xml 220 232 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 243 258 <span type="species:ncbi:9598">Pan troglodytes</span>
To investigate the biological relevance of the "subtle" splicing of CYYR1 mRNA, we performed a bioinformatic analysis of all available sequence databases. CYYR1 locus "subtle" splicing has actually been observed only in Homo sapiens, while in Pan troglodytes the genomic sequence is consistent with its existence.
###end p 82
###begin title 83
Conclusion
###end title 83
###begin p 84
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 310 316 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 374 376 374 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
We have described a new "subtle" splicing isoform for CYYR1 locus and alterations of sequence and expression of this gene in a large series of NE tumors. The CYYR1 mRNA isoform expression level was comparable in tumor samples and normal tissues, and a missense mutation was identified in one tumor sample. The CYYR1 CAG- isoform was significantly more expressed than the CAG+ isoform in NE tumor as well as in control samples investigated. Further investigations are necessary to clarify the functional role of CYYR1 products in both normal and neoplastic cells.
###end p 84
###begin title 85
Abbreviations
###end title 85
###begin p 86
B2M, beta-2 microglobulin; BLAST, basic local alignment search tool; BLASTN, Blast nucleotide-nucleotide; cDNA, DNA complementary to RNA; CDS, coding sequence; dbSNP, single nucleotide polymorphism database; dNTP, deoxyribonucleotide triphosphate; DNES, diffuse neuroendocrine system; EST, expressed sequence tag; htgs, high throughput genomic sequences; IGF1R, insulin-like growth factor 1 receptor; mRNA, messenger RNA; NCBI, National Center for Biotechnology Information; NE, neuroendocrine; nr, non redundant; RT-PCR, reverse transcription - polymerase chain reaction; SNP, single nucleotide polymorphism; TAE, tris-acetate-EDTA; TBE, tris-borate-EDTA.
###end p 86
###begin title 87
Competing interests
###end title 87
###begin p 88
The author(s) declare that they have no competing interests.
###end p 88
###begin title 89
Authors' contributions
###end title 89
###begin p 90
LV designed the study, carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. FFr discussed the molecular genetics and bioinformatics data. SAH prepared and provided the NE tumor biological samples. SC and RC participated in molecular genetics analysis and result interpretation. LL and FFa were involved in statistical and bioinformatics data generation and interpretation. PC and MZ partecipated in study coordination and supervision. DC prepared and provided the NE tumor biological samples and participated in data discussion and drafting the whole manuscript. PS performed the statistical analysis and participated in study design and discussion. All authors read, discussed and approved the final manuscript.
###end p 90
###begin title 91
Pre-publication history
###end title 91
###begin p 92
The pre-publication history for this paper can be accessed here:
###end p 92
###begin p 93

###end p 93
###begin title 94
Supplementary Material
###end title 94
###begin title 95
Additional file 1
###end title 95
###begin p 96
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RNA sample list</bold>
###xml 17 25 <span type="species:ncbi:9606">Patients</span>
RNA sample list. Patients and samples summary data table.
###end p 96
###begin p 97
Click here for file
###end p 97
###begin title 98
Additional file 2
###end title 98
###begin p 99
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GenBank accession numbers of <italic>CYYR1 </italic>mRNA-related sequences found by bioinformatic analysis</bold>
###xml 155 161 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
GenBank accession numbers of CYYR1 mRNA-related sequences found by bioinformatic analysis. Table of all non redundant or EST sequence accession numbers of CYYR1 mRNA related sequences available in NCBI databases in April, 2006.
###end p 99
###begin p 100
Click here for file
###end p 100
###begin title 101
Acknowledgements
###end title 101
###begin p 102
This work was supported by grants from "Fondazione del Monte di Bologna e Ravenna", Bologna, Italy to PS, and from "Progetto Strategico - Ateneo di Bologna" to RC. We would like to thank Gabriella Mattei for her excellent technical assistance in cDNA sequencing. The Authors thank Danielle Mitzman for helping revise the manuscript.
###end p 102
###begin article-title 103
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1</italic>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Cysteine and tyrosine-rich 1 (CYYR1), a novel unpredicted gene on human chromosome 21 (21q21.2), encodes a cysteine and tyrosine-rich protein and defines a new family of highly conserved vertebrate-specific genes
###end article-title 103
###begin article-title 104
The neuroendocrine phenotype, cellular plasticity, and the search for genetic switches: redefining the diffuse neuroendocrine system
###end article-title 104
###begin article-title 105
Contributing software to the internet: the Amplify program
###end article-title 105
###begin article-title 106
The design of primer for PCR
###end article-title 106
###begin article-title 107
Quantitative RT-PCR: pitfalls and potential
###end article-title 107
###begin article-title 108
Widespread occurrence of alternative splicing at NAGNAG acceptors contributes to proteome plasticity
###end article-title 108
###begin article-title 109
The Single Nucleotide Polymorphysm Database
###end article-title 109
###begin article-title 110
The dispersed neuroendocrine system
###end article-title 110
###begin article-title 111
###xml 18 52 <span type="species:ncbi:11908">human T-cell leukemia virus type 1</span>
The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process
###end article-title 111
###begin article-title 112
Epitopes in the interacting regions of beta-dystroglycan (PPxY motif) and dystrophin (WW domain)
###end article-title 112
###begin article-title 113
The WW domain: linking cell signalling to the membrane cytoskeleton
###end article-title 113
###begin article-title 114
###xml 108 113 <span type="species:ncbi:9606">human</span>
Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors
###end article-title 114
###begin title 115
Figures and Tables
###end title 115
###begin p 116
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CYYR1 </italic>mutation in an NE tumor sample</bold>
CYYR1 mutation in an NE tumor sample. Representative electrophoretograms of a sample with normal sequence NE 15 (A) and the mutated sample NE 16 (B), where a variation (apparently in heterozygotic form) in position 333 of CDS (T replaces C) leads to a P111S amino acid change.
###end p 116
###begin p 117
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Enzymatic digestion of <italic>CYYR1 </italic>CDS RT-PCR products from normal brain and an NE tumor</bold>
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 237 239 237 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Enzymatic digestion of CYYR1 CDS RT-PCR products from normal brain and an NE tumor. Gel electrophoresis analysis of CYYR1 CDS RT-PCR products, from normal brain and NE 16, after PstI digestion. Expected size bands (CAG- form: 605 bp, CAG+ form: 427 bp and 181 bp) were obtained in both samples. M1: GeneRuler marker, 500 ng; M2: DNA M5 marker, 250 ng.
###end p 117
###begin p 118
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RT-PCR of <italic>CYYR1 </italic>mRNA isoforms</bold>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 168 170 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
RT-PCR of CYYR1 mRNA isoforms. An example of agarose gel loaded with duplicated RT-PCR products: B2M (lanes 1-6, 586 bp), CYYR1 CAG- (lanes 7-12, 321 bp), and CYYR1 CAG+ (lanes 13-18, 324 bp) mRNAs for samples NE 16, NE 17 and NE 18, respectively from left to right. DNA M5 marker (M1 and M2, 250 ng and 500 ng, respectively) were used for quantification by Gel Doc 2000 software.
###end p 118
###begin p 119
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CYYR1 </italic>exon 3/exon 4 junction and relative amino acids codified</bold>
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 129 131 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 316 318 316 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G </bold>
###xml 347 349 347 349 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A </bold>
###xml 363 365 363 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink">M </bold>
###xml 77 82 <span type="species:ncbi:9606">human</span>
CYYR1 exon 3/exon 4 junction and relative amino acids codified. Alignment of human CYYR1 mRNA sequence, encompassing the CAG-/CAG+ with the corresponding mRNA sequences from other species. The symbol * is used to indicate the exon/exon junction. Predicted amino acid is shown aligned to the first base of its codon; G = glycin, polar not charged; A = alanine and M = methionine, not polar.
###end p 119
###begin p 120
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CYYR1 </italic>intron 3/exon 4 boundary</bold>
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
CYYR1 intron 3/exon 4 boundary. Comparison of CYYR1 57 bases at 3' of intron 3 and 25 bases at 5' of exon 4 in some mammalian species. The symbol * indicates GenBank sequences from ''htgs'' (draft) division. In blue: splicing sites; in magenta: putative branch points (A). In B: comparison of the putative branch sites (the underscored regions in A); in yellow: high identity regions.
###end p 120
###begin p 121
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 protein sequences</bold>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 220 222 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYYR1 </italic>
###xml 349 351 349 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
CYYR1 protein sequences. Manual alignment of the vertebrate CYYR1 protein sequences available in GenBank (nr or EST divisions). Only the partial amino acid sequence encompassing the sequence corresponding to the CAG+/CAG- exon junction is shown. The highly conserved YP amino acids are highlighted in yellow. In blue the alanine (A) in the CYYR1 CAG+ isoform.
###end p 121

